Thermo Fisher Scientific Inc. (NYSE:TMO) Holdings Raised by Thrive Wealth Management LLC

Thrive Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,119 shares of the medical research company’s stock after purchasing an additional 339 shares during the period. Thrive Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $1,813,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of TMO. WCM Investment Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after buying an additional 2,928 shares during the last quarter. Summa Corp. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $418,000. Phoenix Holdings Ltd. lifted its holdings in shares of Thermo Fisher Scientific by 21.4% during the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after buying an additional 1,654 shares during the last quarter. S. R. Schill & Associates lifted its holdings in shares of Thermo Fisher Scientific by 106.3% during the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after buying an additional 792 shares during the last quarter. Finally, Tsfg LLC lifted its holdings in shares of Thermo Fisher Scientific by 8.3% during the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after buying an additional 19 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,000 shares of company stock worth $12,532,780. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO traded up $3.58 during mid-day trading on Friday, reaching $554.36. The company’s stock had a trading volume of 59,773 shares, compared to its average volume of 1,502,673. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The stock has a market cap of $211.61 billion, a P/E ratio of 35.33, a PEG ratio of 2.60 and a beta of 0.79. The business has a 50-day simple moving average of $574.51 and a two-hundred day simple moving average of $562.27. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on TMO shares. JPMorgan Chase & Co. raised their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. Evercore ISI raised their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Robert W. Baird cut their price objective on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. The Goldman Sachs Group raised their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Finally, HSBC lifted their price target on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $607.94.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.